{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:33Z","timestamp":1740123333489,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Although the incidence of distant relapse is decreasing, 20\u201330% of patients with early breast cancer die of metastasis. The aim of this study is to characterize patients with metastasis-free survival(MFS) less than 5\u00a0years, to analyze the most probable site of metastases according to the internally and externally validated BRENDA-score. The BRENDA-score is a combination of the biological subtype and clinical staging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>3832 patients with primary diagnosis of breast cancer and either distant metastatic recurrence within 5\u00a0years or MFS\u2009\u2265\u20095\u00a0years were assigned to this study. Patients were classified for metastatic recurrence according to the BRENDA-score. 1765 patients were in a validation set. Statistical methods were Kaplan\u2013Meier curves, Cox regression analysis, Exhausted CHAID, likelihood-ratio tests and the Nearest Neighbor Estimation method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a significant(p\u2009&lt;\u20090.001) difference between the Kaplan\u2013Meier MFS-functions of M0-patients stratified by BRENDA-score. The BRENDA score outperforms intrinsic subtypes and the Nottingham prognostic score. It fits the original data and the validation set equally well (p\u2009=\u20090.179).There was a significant(p\u2009&lt;\u20090.001) difference between mean BRENDA-Index for patients with MFS\u2009&lt;\u20095y(21.0\u2009\u00b1\u20099.0) and patients with MFS\u2009\u2265\u20095y(mean BRENDA-Index 11.7\u2009\u00b1\u20098.2). 55.6% of the very high risk patients(BRENDA-Index\u2009\u2265\u200927) had metastases within 5\u00a0years. The most likely primary metastatic site was bone(30%) followed by liver(19%) and lung(18%). The discriminatory ability(areas under the time dependent ROC curve) of the BRENDA score is good to acceptable for the first 5\u00a0years. In the very low\/low risk (intermediate, high\/very high) risk group 50% of all metastases were diagnosed within 26\u00a0months. Guideline adherence had a highly significant influence on outcome independent of the risk group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The evaluation showed that the BRENDA-Score is a robust predictive tool for breast cancer recurrence and site of metastases in the first five years after diagnosis. It outperforms intrinsic subtypes and the Nottingham prognostic score. The BRENDA-score could be a tool for a risk orientated and targeted follow up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-06898-z","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:05:18Z","timestamp":1679871918000},"page":"173-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-5344","authenticated-orcid":false,"given":"Florian","family":"Ebner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davut","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Wischnewsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"31","key":"6898_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.breast.2016.06.017","volume":"1","author":"BL Bychkovsky","year":"2017","unstructured":"Bychkovsky BL, Lin NU (2017) Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often? Breast 1(31):318\u2013324","journal-title":"Breast"},{"issue":"6","key":"6898_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/cncr.29811","volume":"122","author":"EE Hahn","year":"2016","unstructured":"Hahn EE, Tang T, Lee JS, Munoz-Plaza CE, Shen E, Rowley B et al (2016) Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care? Cancer 122(6):908\u2013916","journal-title":"Cancer"},{"issue":"3","key":"6898_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10549-015-3341-3","volume":"150","author":"K Kast","year":"2015","unstructured":"Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O et al (2015) Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat 150(3):621\u2013629","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6898_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10549-020-05597-3","volume":"181","author":"M Van Mechelen","year":"2020","unstructured":"Van Mechelen M, Van Herck A, Punie K, Nevelsteen I, Smeets A, Neven P et al (2020) Behavior of metastatic breast cancer according to subtype. Breast Cancer Res Treat 181(1):115\u2013125","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"6898_CR5","doi-asserted-by":"publisher","first-page":"27990","DOI":"10.18632\/oncotarget.15856","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q et al (2017) Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study. Oncotarget 8(17):27990\u201327996","journal-title":"Oncotarget"},{"issue":"4","key":"6898_CR6","first-page":"280","volume":"39","author":"I Veys","year":"2018","unstructured":"Veys I (2018) Follow-up of breast cancer patients by general practitioner. Rev Med Brux 39(4):280\u2013286","journal-title":"Rev Med Brux"},{"issue":"2","key":"6898_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10549-018-05090-y","volume":"174","author":"J Malmgren","year":"2019","unstructured":"Malmgren J, Hurlbert M, Atwood M, Henry M, Kaplan G, Kaplan HG (2019) Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival 1990\u20132011. Breast Cancer Res Treat 174(2):505\u2013514","journal-title":"Breast Cancer Res Treat"},{"key":"6898_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5292-2","volume":"19","author":"F Ebner","year":"2019","unstructured":"Ebner F, W\u00f6ckel A, Schwentner L, Blettner M, Janni W, Kreienberg R et al (2019) Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival? BMC Cancer 19:1. https:\/\/doi.org\/10.1186\/s12885-019-5292-2","journal-title":"BMC Cancer"},{"key":"6898_CR9","doi-asserted-by":"crossref","unstructured":"Schwentner L, W\u00f6ckel A, K\u00f6nig J, Janni W, Ebner F, Blettner M, et al. Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients. 2013. http:\/\/www.biomedcentral.com\/1471-2407\/13\/487","DOI":"10.1186\/1471-2407-13-487"},{"issue":"3","key":"6898_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-013-2772-y","volume":"142","author":"R Wolters","year":"2013","unstructured":"Wolters R, W\u00f6ckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R et al (2013) Comparing the outcome between multicentric and multifocal breast cancer: What is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat 142(3):579\u2013590","journal-title":"Breast Cancer Res Treat"},{"key":"6898_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1993.464","volume":"68","author":"LJ Schouten","year":"1993","unstructured":"Schouten LJ, Jager JJ, Van Den Brandt PA, Schouten LJ (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer 68:1","journal-title":"Br J Cancer"},{"issue":"8","key":"6898_CR12","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Off J Eur Soc Med Oncol 22(8):1736\u20131747","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"6898_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-013-2620-0","volume":"140","author":"EH Lips","year":"2013","unstructured":"Lips EH, Mulder L, De Ronde JJ, Mandjes IAM, Koolen BB, Wessels LFA et al (2013) Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 140(1):63\u201371","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"6898_CR14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796\u20131804","journal-title":"J Clin Oncol"},{"issue":"1","key":"6898_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/0284186X.2016.1237778","volume":"56","author":"A Ehinger","year":"2017","unstructured":"Ehinger A, Malmstr\u00f6m P, Bendahl PO, Elston CW, Falck AK, Forsare C et al (2017) Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol 56(1):68\u201374","journal-title":"Acta Oncol"},{"issue":"7","key":"6898_CR16","first-page":"8500","volume":"8","author":"J Li","year":"2015","unstructured":"Li J, Chen Z, Su K, Zeng J (2015) Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol 8(7):8500","journal-title":"Int J Clin Exp Pathol"},{"key":"6898_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/cancers13133121","volume":"13","author":"M Wischnewsky","year":"2021","unstructured":"Wischnewsky M, Schwentner L, Diessner JD, De Gregorio A, Joukhadar R, Davut D et al (2021) BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients. Cancers (Basel) 13:13","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6898_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337\u2013344","journal-title":"Biometrics"},{"key":"6898_CR19","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe A. S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Leitlinienreport 4.1 https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/. 2019 [cited 2020 Oct 20]. p. 1\u2013422. http:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Mammakarzinom_4_0\/LL_Mammakarzinom_Langversion_Konsultationsfassung_Version_0.4.1.pdf"},{"issue":"8","key":"6898_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.21037\/atm-20-2808","volume":"8","author":"J Chu","year":"2020","unstructured":"Chu J, Yang D, Wang L, Xia J (2020) Nomograms predicting survival for all four subtypes of breast cancer: a SEER-based population study. Ann Transl Med 8(8):544\u2013544","journal-title":"Ann Transl Med"},{"key":"6898_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1051\/vcm\/2020001","volume":"1","author":"M Lin","year":"2020","unstructured":"Lin M, Jin Y, Jin J, Wang B, Hu X, Zhang J et al (2020) A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer. Cancer Med 1:1\u201312","journal-title":"Cancer Med"},{"issue":"20","key":"6898_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/atm.2019.10.10","volume":"7","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yang Y, Chen Z, Zhu T, Wu J, Su F et al (2019) Development and validation of a novel nomogram for predicting distant metastasis-free survival among breast cancer patients. Ann Transl Med 7(20):537\u2013537","journal-title":"Ann Transl Med"},{"issue":"11","key":"6898_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.acra.2015.05.009","volume":"22","author":"CS Giess","year":"2015","unstructured":"Giess CS, Poole PS, Chikarmane SA, Sippo DA, Birdwell RL (2015) Screening Breast MRI in Patients Previously Treated for Breast Cancer: Diagnostic Yield for Cancer and Abnormal Interpretation Rate. Acad Radiol 22(11):1331\u20131337","journal-title":"Acad Radiol"},{"issue":"16","key":"6898_CR24","doi-asserted-by":"publisher","first-page":"e19676","DOI":"10.1097\/MD.0000000000019676","volume":"99","author":"M Kwon","year":"2020","unstructured":"Kwon M, Ko EY, Han B-K, Ko ES, Choi JS, Park KW (2020) Diagnostic performance of abbreviated breast MRI for screening of women with previously treated breast cancer. Medicine (Baltimore) 99(16):e19676","journal-title":"Medicine (Baltimore)"},{"key":"6898_CR25","doi-asserted-by":"crossref","unstructured":"Cheng FT-F, Lapke N, Wu C-C, Lu Y-J, Chen S-J, Yu P-N, et al. Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer. Case Rep Oncol Med 2019; 2019:1\u20134","DOI":"10.1155\/2019\/6545298"},{"issue":"12","key":"6898_CR26","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.7150\/jca.24445","volume":"9","author":"Z Lin","year":"2018","unstructured":"Lin Z, Yan S, Zhang J, Pan Q (2018) A nomogram for distinction and potential prediction of liver metastasis in breast cancer patients. J Cancer 9(12):2098\u20132106","journal-title":"J Cancer"},{"issue":"7","key":"6898_CR27","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00432-019-02904-4","volume":"145","author":"V Voelkel","year":"2019","unstructured":"Voelkel V, Draeger T, Groothuis-Oudshoorn CGMM, de Munck L, Hueting T, Gerken M et al (2019) Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. J Cancer Res Clin Oncol 145(7):1823\u20131833","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"6898_CR28","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.7150\/jca.30386","volume":"10","author":"YX Zhao","year":"2019","unstructured":"Zhao YX, Liu YR, Xie S, Jiang YZ, Shao ZM (2019) A nomogram predicting lymph node metastasis in t1 breast cancer based on the surveillance, epidemiology, and end results program. J Cancer 10(11):2443\u20132449","journal-title":"J Cancer"},{"key":"6898_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.breast.2020.08.004","volume":"53","author":"S Lin","year":"2020","unstructured":"Lin S, Mo H, Li Y, Guan X, Chen Y, Wang Z et al (2020) Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China. Breast 53:172\u2013180. https:\/\/doi.org\/10.1016\/j.breast.2020.08.004","journal-title":"Breast"},{"issue":"3","key":"6898_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10549-018-4958-9","volume":"172","author":"M Takada","year":"2018","unstructured":"Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H et al (2018) Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Res Treat 172(3):611\u2013618","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"6898_CR31","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2009.24.6314","volume":"28","author":"O Graesslin","year":"2010","unstructured":"Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L et al (2010) Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28(12):2032\u20132037","journal-title":"J Clin Oncol"},{"key":"6898_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-019-1371-4","volume":"14","author":"X Chu","year":"2019","unstructured":"Chu X, Li S, Xia B, Chu L, Yang X, Ni J et al (2019) Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): Implications for PCI optimization in limited-stage small cell lung cancer. Radiat Oncol 14:1","journal-title":"Radiat Oncol"},{"key":"6898_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2020.09.005","volume":"25","author":"J Yu","year":"2020","unstructured":"Yu J, Ouyang W, Yang Y, Zhang X, Zhou Y, Zhang J et al (2020) Prophylactic cranial irradiation for extensive-stage small cell lung cancer: Analysis based on active brain MRI surveillance. Clin Transl Radiat Oncol 25:16\u201321","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"6898_CR34","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/bjc.2015.308","volume":"113","author":"Y Delpech","year":"2015","unstructured":"Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C et al (2015) Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer 113(7):1003\u20131009","journal-title":"Br J Cancer"},{"issue":"3","key":"6898_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-015-3490-4","volume":"152","author":"A Witteveen","year":"2015","unstructured":"Witteveen A, Vliegen IMH, Sonke GS, Klaase JM, IJzerman MJ, Siesling S (2015) Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat 152(3):627\u2013636","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6898_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-020-05847-4","volume":"184","author":"L Saltb\u00e6k","year":"2020","unstructured":"Saltb\u00e6k L, Horsboel TA, Offersen BV, Andersson M, Friberg AS, Skriver SK et al (2020) Patterns in detection of recurrence among patients treated for breast cancer. Breast Cancer Res Treat 184(2):365\u2013373","journal-title":"Breast Cancer Res Treat"},{"key":"6898_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-020-05753-x","volume":"20","author":"I Ricci-Cabello","year":"2020","unstructured":"Ricci-Cabello I, V\u00e1squez-Mej\u00eda A, Canelo-AybarC,Ni\u00f1o De Guzman E, P\u00e9rez-Bracchiglione J, Rabassa M, et al (2020) Adherence to breast cancer guidelines is associated with better survival outcomes: A systematic review and meta-analysis of observational studies in EU countries. BMC Health Serv Res 20:1","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"6898_CR38","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT et al (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(8):1194\u20131220","journal-title":"Ann Oncol"},{"key":"6898_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012425.pub2","author":"BL H\u00f8eg","year":"2019","unstructured":"H\u00f8eg BL, Bidstrup PE, Karlsen RV, Friberg AS, Albieri V, Dalton SO et al (2019) Follow-up strategies following completion of primary cancer treatment in adult cancer survivors. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD012425.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"6898_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL et al (2016) American cancer society\/American society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol 34(6):611\u2013635","journal-title":"J Clin Oncol"},{"issue":"2","key":"6898_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-018-5002-9","volume":"173","author":"V Sopik","year":"2019","unstructured":"Sopik V, Sun P, Narod SA (2019) Predictors of time to death after distant recurrence in breast cancer patients. Breast Cancer Res Treat 173(2):465\u2013474","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6898_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-015-0023-0","volume":"4","author":"J Xie","year":"2015","unstructured":"Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V et al (2015) Clinical outcomes among HR+\/HER2\u2212 metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol 4(1):31","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"6898_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10549-019-05334-5","volume":"177","author":"V Giannakeas","year":"2019","unstructured":"Giannakeas V, Narod SA (2019) A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. Breast Cancer Res Treat 177(3):691\u2013703","journal-title":"Breast Cancer Res Treat"},{"key":"6898_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-67393-9","volume":"10","author":"D Hempel","year":"2020","unstructured":"Hempel D, Ebner F, Garg A, Trepotec Z, Both A, Stein W et al (2020) Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. Sci Rep 10:1. https:\/\/doi.org\/10.1038\/s41598-020-67393-9","journal-title":"Sci Rep"},{"key":"6898_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10408363.2019.1670615","volume":"57","author":"E Tzanikou","year":"2020","unstructured":"Tzanikou E, Lianidou E (2020) The potential of ctDNA analysis in breast cancer. Crit Rev Clin Lab Sci 57:54\u201372. https:\/\/doi.org\/10.1080\/10408363.2019.1670615","journal-title":"Crit Rev Clin Lab Sci"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06898-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06898-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06898-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T02:05:44Z","timestamp":1682733944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06898-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6898"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06898-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Include appropriate disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}